Medicine Overview

Indication

Know Medicine, Follow Guideline

Adult Dose

Clinical InformationAdministration Information
Indication: Type 2 Diabetes Mellitus
Age: Adults
Dose: Tablet – 10 mg/5 mg
Frequency: once daily in the morning
Note: Indicated as an adjunct to diet and exercise to improve glycemic control when both empagliflozin and linagliptin are appropriate treatments. Hepatic impairment: No dose adjustment required
Indication: Type 2 Diabetes Mellitus
Age: Adults
Condition: If needed and tolerated
Dose: Tablet – 25 mg/5 mg
Frequency: once daily
Note: Dose may be increased to this level. Hepatic impairment: No dose adjustment required

Child Dose

Clinical InformationAdministration Information
Age: Child
Dose: No approved pediatric dosage available
Note: No approved pediatric dosage available

Renal Dose

Clinical InformationAdministration Information
Condition: Renal impairment eGFR greater than 45 mL/min/1.73 m2
Dose: Not specified
Note: No dose adjustment required
Condition: Renal impairment eGFR 30-45 mL/min/1.73 m2
Dose: Not specified
Note: Do not initiate drug. Discontinued if eGFR is persistently drops to less than 45 mL/min/1.73 m2
Administration
  • May be taken with or without food
  • Take at same time each day
Side Effect

Drug Interaction

Drug NameRisk Factors
Insulin, sulphonylureas
May increase risk of hypoglycemia
UGT enzyme inducers
Risk of decreased efficacy

Disease Interaction

Disease NameRisk Factors
No specific contraindications listed
Monitor for general drug reactions

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage

Details coming soon

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.